ArticleJournal of experimental & clinical cancer research : CR2019
WISP2 exhibits its potential antitumor activity via targeting ERK and E-cadherin pathways in esophageal cancer cells.
Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- A WISPer of Hope? WISP2 and Vasculogenic Mimicry in Gastric Cancer-Implications for EMT and Tumor Plasticity.Digestive diseases and sciences · 2026Article
- WISP2 Overexpression Is Associated with Reduced Vasculogenic Mimicry and Epithelial-Mesenchymal Transition in Gastric Cancer.Digestive diseases and sciences · 2026Article
- Unraveling the impact of hsa-miR-518c-5p on placental health: mechanistic insights into preeclampsia pathogenesis.Journal of translational medicine · 2025Article
- Elevation of Plasma IL-15 and RANTES as Potential Biomarkers of Healing in Chronic Venous Ulcerations: A Pilot Study.Biomolecules · 2025Article
- Matricellular proteins: Potential biomarkers in head and neck cancer.Journal of cell communication and signaling · 2024Review
- Expressions and clinical significance of CCN5 and E-cadherin in primary and recurrent lesions of breast cancer.Frontiers in genetics · 2024Article
- [Lowered expression of CCN5 in endometriotic tissues promotes proliferation, migration and invasion of endometrial stromal cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Aberrant expression of SPAG6 and NM23 predicts poor prognosis of human osteosarcoma.Frontiers in genetics · 2022Article
- The CCN axis in cancer development and progression.Journal of cell communication and signaling · 2021Review
- Conditioned Media of Adipose-Derived Stem Cells Suppresses Sidestream Cigarette Smoke Extract Induced Cell Death and Epithelial-Mesenchymal Transition in Lung Epithelial Cells.International journal of molecular sciences · 2021Article
- Correction to "Suppression of Esophageal Squamous Cell Carcinoma Development by Mechanosensitive Protein Piezo1 Downregulation".ACS omega · 2021Article
- Suppression of Esophageal Squamous Cell Carcinoma Development by Mechanosensitive Protein Piezo1 Downregulation.ACS omega · 2021Article
- Clinical significance of CCN5 and mutant p53 in primary and recurrent lesions of breast cancer.American journal of translational research · 2021Article
- Identifying Critical States of Complex Diseases by Single-Sample Jensen-Shannon Divergence.Frontiers in oncology · 2021Article
- CCN Family Proteins in Cancer: Insight Into Their Structures and Coordination Role in Tumor Microenvironment.Frontiers in genetics · 2021Review
- WISP2 promotes cell proliferation via targeting ERK and YAP in ovarian cancer cells.Journal of ovarian research · 2020Article
- Identification of candidate aberrantly methylated and differentially expressed genes in Esophageal squamous cell carcinoma.Scientific reports · 2020Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsEmerging evidence has demonstrated that WISP2 is critically involved in cell proliferation, migration, invasion and metastasis in cancers. However, the function of WISP2 in esophageal squamous cell carcinoma (ESCC) is largely unclear. Therefore, we aim to explore the effects and the potential mechanism of WISP2 on proliferation and motility and invasion of ESCC cells.
methodsCell proliferation was detected by MTT assay and apoptosis was measured by FACS in ESCC cells after WISP2 downregulation and overexpression. Cell migration and invasion were analyzed by wound healing assay and transwell migration assay, respectively. The expression of ERK-1/2, Slug and E-cadherin was measured by Western blot respectively. IHC was performed to measure the expression of WISP2 in ESCC tissues.
resultsWISP2 overexpression is associated with survival in ESCC patients. WISP2 overexpression inhibited cell growth and induced cell apoptosis, suppressed cell migration and invasion in ESCC cells. Moreover, WISP overexpression retarded tumor growth in mouse model. WISP2 downregulation enhanced cell growth, inhibited apoptosis, promoted cell migration and invasion in ESCC cells. Mechanistically, WISP2 exerts its tumor suppressive functions via regulation of ERK1/2, Slug, and E-cadherin in ESCC cells.
conclusionsOur findings suggest that activation of WISP2 could be a useful therapeutic strategy for the treatment of ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.